ReviewNature reviews. Urology2023
Health-related quality of life after curative treatment for muscle-invasive bladder cancer.
Review in Nature reviews. Urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Longitudinal Impact of Urinary Diversion on Health-Related Quality of Life After Radical Cystectomy: A Multicenter Study in Japan.Cancer science · 2026Article
- Urinary bladder cancer needs more attention - recommendations for health care professionals and politicians in the European Union.Nature reviews. Urology · 2026Review
- The Interplay of Cumulative Perioperative Morbidity and Health-related Quality of Life After Radical Cystectomy-Prospective Evidence from the COMPACT Registry.European urology open science · 2025Article
- Application of single-cell and spatial omics in deciphering cellular hallmarks of cancer drug response and resistance.Journal of hematology & oncology · 2025Review
- Impact of late effects after treatment for bladder cancer with radical cystectomy on Quality of life: a case-control study.Acta oncologica (Stockholm, Sweden) · 2025Article
- Engineered targeting OIP5 sensitizes bladder cancer to chemotherapy resistance via TRIP12-PPP1CB-YBX1 axis.Oncogene · 2024Article
- Retinoids and EZH2 inhibitors cooperate to orchestrate anti-oncogenic effects on bladder cancer cells.Cancer gene therapy · 2024Article
- Development and preliminary validation of a PROS scale for Chinese bladder cancer patients with abdominal stoma.Scientific reports · 2024Article
- Efficiency of bladder-sparing strategies for bladder cancer: an umbrella review.Therapeutic advances in medical oncology · 2024Review
- Health Related Quality of Life in Patients with Bladder Cancer Receiving a Radical Cystectomy.Cancers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Muscle-invasive bladder cancer (MIBC) is an aggressive disease for which the gold-standard treatment is radical cystectomy (RC) in combination with cisplatin-based neoadjuvant chemotherapy. Bladder-sparing strategies such as trimodal therapy (TMT) have also emerged to improve health-related quality of life (HRQoL) of patients. However, an improved understanding of the effect of all these treatment modalities on HRQoL is essential to provide personalized patient care. Different combinations of generic, cancer-specific and bladder cancer-specific questionnaires can be used as instruments for HRQoL evaluation in patients with MIBC before and after curative treatments, which can largely affect multiple domains of HRQoL including general health as well as physical, functional, social and emotional well-being. However, diagnosis of MIBC per se is also likely to affect HRQoL, and the perspective of cure after RC or TMT could induce a return to baseline HRQoL values for most of these domains. A considerable amount of data on HRQoL after RC is available, but conflicting results have been reported regarding the effect of urinary diversion (ileal conduit or orthotopic neobladder) and surgical approach (open or robotic surgery) on patient quality of life. Data on HRQoL after TMT are scarce, and additional comparative studies including patients receiving RC (especially using ileal orthotopic neobladder) are needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.